• Citer

Is there a rationale for the chronic use of phosphodiesterase-5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia?

par Roumeguere, Thierry ;Zouaoui Boudjeltia, Karim ;Hauzeur, Claude;Schulman, Claude ;Vanhaeverbeek, Michel ;Wespes, Eric
Référence BJU international, 104, 4, page (511-517)
Publication Publié, 2009-08

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Titre:	Is there a rationale for the chronic use of phosphodiesterase-5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia?
Auteur:	Roumeguere, Thierry; Zouaoui Boudjeltia, Karim; Hauzeur, Claude; Schulman, Claude; Vanhaeverbeek, Michel; Wespes, Eric
Informations sur la publication:	BJU international, 104, 4, page (511-517)
Statut de publication:	Publié, 2009-08
Sujet CREF:	Sciences bio-médicales et agricoles
Mots-clés:	BPH
	CGMP
	Erectile dysfunction
	Inhibitors
	LUTS
	Phosphodiesterase 5
MeSH keywords:	Aged
	Carbolines -- administration & dosage -- adverse effects
	Erectile Dysfunction -- drug therapy -- etiology
	Humans
	Imidazoles -- administration & dosage -- adverse effects
	Male
	Middle Aged
	Phosphodiesterase Inhibitors -- administration & dosage -- adverse effects
	Piperazines -- administration & dosage -- adverse effects
	Prostatic Hyperplasia -- complications
	Prostatism -- drug therapy -- etiology
	Purines -- administration & dosage -- adverse effects
	Quality of Life
	Quinazolines -- administration & dosage -- adverse effects
	Sulfones -- administration & dosage -- adverse effects
	Treatment Outcome
	Triazines -- administration & dosage -- adverse effects
Note générale:	Journal Article
	Review
	FLWIN
	SCOPUS: ar.j
Langue:	Anglais
Identificateurs:	urn:issn:1464-4096
	info:doi/10.1111/j.1464-410X.2009.08418.x
	info:pii/BJU8418
	info:scp/69849087363
	info:pmid/19239452